Clinical and Translational Oncology

, Volume 16, Issue 3, pp 330–335 | Cite as

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

  • Y. Homma
  • K. Taniguchi
  • M. Nakazawa
  • R. Matsuyama
  • R. Mori
  • K. Takeda
  • Y. Ichikawa
  • K. Tanaka
  • I. Endo
Research Article

Abstract

Purpose

Regulatory T cells (Tregs) play a role in the immunosuppressive state in pancreatic cancer patients. We aimed to evaluate the changes of immune cells population including Tregs caused by gemcitabine (GEM)-based chemotherapy.

Methods

Fifty-three patients with pancreatic cancer were enrolled in this study, of which 32 received GEM- based chemotherapy. Blood samples were collected before and at least 2 weeks after the last dose of chemotherapy. The peripheral blood mononuclear cells (PBMCs) were subjected to flow cytometry analysis after labeling with anti-CD4, anti-CD25, and anti-Foxp3 antibodies. Other lymphocytes and NK cell markers were also measured. The proliferative capacity of PBMCs stimulated with anti-CD3 was analyzed using H3 thymidine.

Results

The percentage and number of Tregs were significantly decreased after chemotherapy (p = 0.032, p = 0.003, respectively). The other immune cells and the proliferative capacity did not change.

Conclusion

This study showed that GEM-based chemotherapy produced an immunomodulatory effect via the depletion of Tregs.

Keywords

Pancreatic cancer Lymphocytes Regulatory T cell Gemcitabine 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.PubMedCrossRefGoogle Scholar
  2. 2.
    Wray CJ, Ahmad SA, Matthews JB, Lowy AM. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128:1626–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMedGoogle Scholar
  4. 4.
    Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemother Pharmacol. 2012;69:1197–204.PubMedCrossRefGoogle Scholar
  5. 5.
    Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005;54:915–25.PubMedCrossRefGoogle Scholar
  6. 6.
    Thornton AM, Shevach EM. CD4;CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287–96.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167–74.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003;98:1089–99.PubMedCrossRefGoogle Scholar
  9. 9.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65:2457–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756–61.PubMedGoogle Scholar
  12. 12.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61:4766–72.PubMedGoogle Scholar
  13. 13.
    Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Shlom J, et al. Enhanced functionality of CD4+CD25(high) Foxp3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res. 2008;14:1032–40.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang WC, Li CH, Huang SC, Chang DY, Chou LY, Shue BC. Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma. Cancer. 2010;116:5777–88.PubMedCrossRefGoogle Scholar
  15. 15.
    Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency of regulatory T cells in peripheral blood and in tumor-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107:1500–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of Foxp3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M, et al. Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 2006;33:386–90.PubMedCrossRefGoogle Scholar
  18. 18.
    Sobin LH, Wittekind CL, editors. TNM classification of malignant tumors. 6th ed. New York: John Wiley & Sons, Inc.; 2002.Google Scholar
  19. 19.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRefGoogle Scholar
  20. 20.
    Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenberg SO. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2000;59:1593–600.CrossRefGoogle Scholar
  22. 22.
    Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol. 2000;164:6230–6.PubMedGoogle Scholar
  23. 23.
    Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol. 2008;129:219–29.PubMedCrossRefGoogle Scholar
  25. 25.
    Emens LA. Chemoimmunotherapy. Cancer J. 2010;16:295–303.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Emens LA. Chemotherapy and tumor immunity: an unexpected collaboration. Front Biosci. 2008;13:249–57.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Nowak AK, Robbinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy. Cancer Res. 2002;62:2353–8.PubMedGoogle Scholar
  29. 29.
    Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713–21.PubMedCrossRefGoogle Scholar
  30. 30.
    Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, Knuth A, et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer. 2011;129:832–8.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • Y. Homma
    • 1
  • K. Taniguchi
    • 1
  • M. Nakazawa
    • 2
  • R. Matsuyama
    • 1
  • R. Mori
    • 1
  • K. Takeda
    • 1
  • Y. Ichikawa
    • 1
  • K. Tanaka
    • 1
  • I. Endo
    • 1
  1. 1.Department of Gastroenterological SurgeryYokohama City University School of MedicineYokohamaJapan
  2. 2.Department of Experimental Animal ScienceYokohama City University Graduate School of MedicineYokohamaJapan

Personalised recommendations